Autologous expanded tumour infiltrating lymphocytes(Iovance Biotherapeutics)

N/A

Report date: 2026/05/16 20:00:17

Base Information

Drug NameAutologous expanded tumour infiltrating lymphocytes(Iovance Biotherapeutics)
Drug Alias NameAutologous expanded tumour infiltrating lymphocytes(Iovance Biotherapeutics)Autologous tumour infiltrating lymphocytes(Iovance Biotherapeutics)MDA Autologous TILsMDA Autologous Tumor Infiltrating LymphocytesTIL LN-145 +[10] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsSkin MelanomaPoorly Differentiated Thyroid Gland CarcinomaSolid tumours +[28] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIovance Biotherapeutics IncNational Cancer InstituteNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesIovance Biotherapeutics IncH Lee Moffitt Cancer Center & Research InstituteNational Cancer Institute +[4] 
Inactive CompaniesRoswell Park Cancer Institute
Active IndicationsPoorly Differentiated Thyroid Gland CarcinomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[18] 
Inactive IndicationsSkin MelanomaNeoplasm MetastasisUrinary Bladder Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A